Elicia Penuel
Research Subjects
Elicia Penuel has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Andrew G. Polson
Research and Early Development, Genentech Inc., South San Francisco, California.
21 shared publications - Christoph Spiess
Department of Antibody Engineering, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
21 shared publications - Dorothee Nickles
Genentech Research and Early Development, Genentech Inc., South San Francisco, California
21 shared publications - Ely Cosino
Genentech Research and Early Development, Genentech Inc., South San Francisco, California
21 shared publications - Geoff Del Rosario
Genentech Research and Early Development, Genentech Inc., South San Francisco, California
21 shared publications - Greg A. Lazar
Department of Antibody Engineering, Genentech, Inc., South San Francisco, USA
21 shared publications
Latest Publications
- Open Access
Integrative genomic analysis identifies unique immune environments associated with immunotherapy response in diffuse large B cell lymphoma
Most relapsed or refractory diffuse large B cell lymphoma (DLBCL) patients show primary resistance, or relapse after receiving immunotherapies such as CAR T cells, bispecific antibodies, or checkpoint blockade therapy, highlighting the need for a deeper understanding of mechanisms that regulate the immune environment and response to immunotherapy. Therefore, we performed bulk transcriptomic analysis of 862 diagnostic DLBCL specimens and segregated DLBCLs into four unique quadrants defined by cell-of-origin and immune-related gene set expression scores, termed DLBCL-immune quadrants (DLBCL-IQ). These quadrants consisted of activated B cell-like (ABC) hot, ABC cold, germinal center B cell-like (GCB) hot, GCB cold DLBCLs. Unique genomic alterations were enriched in each immune cluster, suggesting that lymphoma-intrinsic alterations modulate the DLBCL immune environment. For instance, SOCS1 loss-of-function mutations were enriched among GCB hot DLBCLs, identifying a putative subset of inflamed DLBCLs that may be inherently susceptible to immunotherapy. Finally, treatment with the CD20 x CD3 bispecific antibody, mosunetuzumab, was associated with significantly improved progression-free survival of GCB hot DLBCL patients, underscoring the importance of our DLBCL-IQs in predicting bispecific antibody efficacy in this disease. Significance This in-depth characterization of DLBCL immune landscapes and associated genomic alterations should catalyze development of rationally designed, combinatorial studies of targeted and immune therapies. Moreover, the association between the immune environment and clinical outcomes to a bispecific antibody is important, and similar analyses can be employed to address how particular DLBCL immune environments influence the efficacy of checkpoint blockade and CAR T cell therapy.
Open AccessIntegrative genomic analysis identifies unique immune environments associated with immunotherapy response in diffuse large B cell lymphoma
Most relapsed or refractory diffuse large B cell lymphoma (DLBCL) patients show primary resistance, or relapse after receiving immunotherapies such as CAR T cells, bispecific antibodies, or checkpoint blockade therapy, highlighting the need for a deeper understanding of mechanisms that regulate the immune environment and response to immunotherapy. Therefore, we performed bulk transcriptomic analysis of 862 diagnostic DLBCL specimens and segregated DLBCLs into four unique quadrants defined by cell-of-origin and immune-related gene set expression scores, termed DLBCL-immune quadrants (DLBCL-IQ). These quadrants consisted of activated B cell-like (ABC) hot, ABC cold, germinal center B cell-like (GCB) hot, GCB cold DLBCLs. Unique genomic alterations were enriched in each immune cluster, suggesting that lymphoma-intrinsic alterations modulate the DLBCL immune environment. For instance, SOCS1 loss-of-function mutations were enriched among GCB hot DLBCLs, identifying a putative subset of inflamed DLBCLs that may be inherently susceptible to immunotherapy. Finally, treatment with the CD20 x CD3 bispecific antibody, mosunetuzumab, was associated with significantly improved progression-free survival of GCB hot DLBCL patients, underscoring the importance of our DLBCL-IQs in predicting bispecific antibody efficacy in this disease. Significance This in-depth characterization of DLBCL immune landscapes and associated genomic alterations should catalyze development of rationally designed, combinatorial studies of targeted and immune therapies. Moreover, the association between the immune environment and clinical outcomes to a bispecific antibody is important, and similar analyses can be employed to address how particular DLBCL immune environments influence the efficacy of checkpoint blockade and CAR T cell therapy.
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures and Legends from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Supplementary Figures and Legends
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures and Legends from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Supplementary Figures and Legends
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Supplemental Table S1: Results of a differential gene expression analysis comparing baseline NK cells to NK cells 24 hours after T cell-dependent bispecific (TDB) treatment.
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Supplemental Table S1: Results of a differential gene expression analysis comparing baseline NK cells to NK cells 24 hours after T cell-dependent bispecific (TDB) treatment.
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Cytokines produced during TDB-mediated killing impact the NK-cell transcriptome and their function.
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Cytokines produced during TDB-mediated killing impact the NK-cell transcriptome and their function.
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Gating strategy and time course of activation for circulating NK cells after Mosunetuzumab treatment.
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Gating strategy and time course of activation for circulating NK cells after Mosunetuzumab treatment.
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
NK cells exposed to TDB-treated cells have increased cytolytic function.
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
NK cells exposed to TDB-treated cells have increased cytolytic function.
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
In vivo CD20-TDB induces systemic cytokine release.
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
In vivo CD20-TDB induces systemic cytokine release.
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures and Legends from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Supplementary Figures and Legends
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures and Legends from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Supplementary Figures and Legends
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Cytokines produced during TDB-mediated killing alters surface protein expression on macrophages.
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
Cytokines produced during TDB-mediated killing alters surface protein expression on macrophages.
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
In vivo CD20-TDB induces systemic cytokine release.
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing
In vivo CD20-TDB induces systemic cytokine release.